Clinical Trial Update: A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the clinical activity of tanespimycin (IPI-504) in hormone-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 2 | Status: COMPLETED